ArticleBiomolecules2026

Complement Activation May Drive the Pathogenicity of Anti-α6 and Anti-β4 Integrin Antibodies In Vivo.

Gefei Du et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.